Presentation Authors: xiaoguang shao*, Jiahua Pan, Yinjie Zhu, Yinjie Zhu, Baijun Dong, Yanqing Wang, Wei Xue, shanghai, China, People's Republic of
Introduction: Prostate cancer (Pca) bone metastases are characterized by abnormal bone remodeling processes and result in the release of components from the osseous metabolism into the blood stream. The objective of this study was to detect the components alteration in serum using Surface-Enhanced Raman Spectroscopy (SERS) and then evaluated the performance of Raman spectra in diagnosis of bone metastases.
Methods: We analyzed serum samples from Pca patients with and without bone metastases using Surface-Enhanced Raman Spectroscopy (SERS) technology. The Principal component analysis was used to extract the signature of Raman spectra and The linear discriminate analysis was used to develop diagnostic algorithm.
Results: A total of 336 Raman spectra of serum were collected from 112 patients, and were compared between Pca patients developed bone metastases and patients had locally confined cancer. The SERS detected more abundant C-N stretching vibration rich proteins, Lipids and CH vibration rich DNA/RNA bases in bloodstream of metastasized patients. The leave-one-out cross-validation method was used to validate the PCA-LDA model and revealed the sensitivity and specificity of 73.8% and 86.2% respectively. The receiver operating characteristic (ROC) curve was used to evaluate the performance diagnostic model, area under the ROC curve was 0.89.
Conclusions: Our results revealed the Raman spectral signature of serum from bone metastasized patients. The PCA-LDA analysis of Raman spectra suggested that SERS could be meaningful technique for prostate cancer bone metastases screening.